###begin article-title 0
###xml 16 29 16 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A, TP53,</italic>
NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 16 29 16 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A, TP53,</italic>
###xml 79 84 <span type="species:ncbi:9606">human</span>
###xml 583 591 <span type="species:ncbi:9606">patients</span>
Somatic genetic CDKN2A, TP53, and DNA content abnormalities are common in many human cancers and their precursors, including esophageal adenocarcinoma (EA) and Barrett's esophagus (BE), conditions for which aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have been proposed as possible chemopreventive agents; however, little is known about the ability of a biomarker panel to predict progression to cancer nor how NSAID use may modulate progression. We aimed to evaluate somatic genetic abnormalities with NSAIDs as predictors of EA in a prospective cohort study of patients with BE.
###end p 2
###begin title 3
Methods and Findings
###end title 3
###begin p 4
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 86 98 86 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A (p16)</italic>
###xml 269 275 269 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 451 452 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 499 500 499 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 665 666 665 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1031 1032 1031 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1229 1230 1229 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 677 685 <span type="species:ncbi:9606">Patients</span>
###xml 763 771 <span type="species:ncbi:9606">patients</span>
###xml 867 875 <span type="species:ncbi:9606">patients</span>
###xml 1086 1098 <span type="species:ncbi:9606">participants</span>
Esophageal biopsies from 243 patients with BE were evaluated at baseline for TP53 and CDKN2A (p16) alterations, tetraploidy, and aneuploidy using sequencing; loss of heterozygosity (LOH); methylation-specific PCR; and flow cytometry. At 10 y, all abnormalities, except CDKN2A mutation and methylation, contributed to EA risk significantly by univariate analysis, ranging from 17p LOH (relative risk [RR] = 10.6; 95% confidence interval [CI] 5.2-21.3, p < 0.001) to 9p LOH (RR = 2.6; 95% CI 1.1-6.0, p = 0.03). A panel of abnormalities including 17p LOH, DNA content tetraploidy and aneuploidy, and 9p LOH was the best predictor of EA (RR = 38.7; 95% CI 10.8-138.5, p < 0.001). Patients with no baseline abnormality had a 12% 10-y cumulative EA incidence, whereas patients with 17p LOH, DNA content abnormalities, and 9p LOH had at least a 79.1% 10-y EA incidence. In patients with zero, one, two, or three baseline panel abnormalities, there was a significant trend toward EA risk reduction among NSAID users compared to nonusers (p = 0.01). The strongest protective effect was seen in participants with multiple genetic abnormalities, with NSAID nonusers having an observed 10-y EA risk of 79%, compared to 30% for NSAID users (p < 0.001).
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
###xml 115 128 115 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53, CDKN2A,</italic>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
A combination of 17p LOH, 9p LOH, and DNA content abnormalities provided better EA risk prediction than any single TP53, CDKN2A, or DNA content lesion alone. NSAIDs are associated with reduced EA risk, especially in patients with multiple high-risk molecular abnormalities.
###end p 6
###begin p 7
###xml 23 29 <span type="species:ncbi:9606">people</span>
###xml 170 178 <span type="species:ncbi:9606">patients</span>
In a ten-year study of people with Barrett's esophagus, nonsteroidal anti-inflamatory drugs were associated with reduced risk of esophageal adenocarcinoma, especially in patients with multiple high-risk molecular abnormalities.
###end p 7
###begin title 8
Editors' Summary
###end title 8
###begin title 9
Background.
###end title 9
###begin p 10
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 578 586 <span type="species:ncbi:9606">patients</span>
###xml 1155 1161 <span type="species:ncbi:9606">People</span>
Normally, the cells in the human body divide only when extra cells are needed, after an injury, for example. Sometimes, however, cells accumulate genetic changes (mutations) that allow them to divide uncontrollably to form a disorganized mass or tumor. If these altered cells also acquire mutations that allow them to spread around the body, a malignant tumor or cancer results. Scientists have identified numerous genetic changes that occur in tumors and are now investigating whether these molecular abnormalities can be used as "biomarkers" to choose the best treatments for patients, to identify who will benefit from cancer-prevention strategies, to detect cancer early, and to predict which cancers are most likely to become life-threatening. This last application is particularly important for cancers with a well-defined premalignant stage. Because the cells in premalignant tissues have acquired some of the genetic changes required for cancer development, they are more likely to become malignant than normal cells. Barrett's esophagus, for example, is a premalignant disorder of the muscular tube that takes food from the mouth to the stomach. People with Barrett's esophagus are much more likely to develop esophageal cancer than the general population.
###end p 10
###begin title 11
Why Was This Study Done?
###end title 11
###begin p 12
###xml 102 108 <span type="species:ncbi:9606">people</span>
###xml 337 345 <span type="species:ncbi:9606">patients</span>
###xml 512 518 <span type="species:ncbi:9606">people</span>
Esophageal cancer is often incurable by the time it is detected, so it would be helpful to know which people with Barrett's esophagus are most likely to develop esophageal cancer-only 1 in 200 of them develop cancer each year. In this study, the researchers evaluated whether a panel of genetic alterations could identify this subset of patients. They also investigated whether the regular use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) affects the risk of developing esophageal cancer in people with Barrett's esophagus-other evidence suggests that NSAIDs may help to prevent several types of cancer, including esophageal cancer.
###end p 12
###begin title 13
What Did the Researchers Do and Find?
###end title 13
###begin p 14
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 566 578 <span type="species:ncbi:9606">participants</span>
###xml 629 641 <span type="species:ncbi:9606">participants</span>
###xml 687 699 <span type="species:ncbi:9606">participants</span>
###xml 1087 1095 <span type="species:ncbi:9606">patients</span>
###xml 1136 1144 <span type="species:ncbi:9606">patients</span>
###xml 1259 1271 <span type="species:ncbi:9606">participants</span>
The researchers took esophageal tissue samples from patients with Barrett's esophagus and looked for alterations in the genes encoding the tumor-suppressor proteins TP53 and CDKN2A. These proteins normally stop cells dividing but are often inactivated in cancer cells by mutation of one of the two gene copies that encode each of them and also loss of the other copy (so-called "loss of heterozygosity" or LOH). The researchers also looked for changes in the cellular DNA content of the samples (tumor cells often contain unusual amounts of DNA) and asked the study participants about their NSAID use before waiting to see which participants developed esophageal cancer. After 10 y, the participants whose tissue samples had LOH of the short arms (p) of Chromosome 17 or 9 (the sites of the genes encoding TP53 and CDKN2A, respectively), or an altered DNA content, were more likely to have developed esophageal cancer than those without these abnormalities; those whose samples contained all three abnormalities had the highest risk of developing esophageal cancer. Overall, just 12% of patients with no abnormalities but nearly 80% of patients with three abnormalities developed esophageal cancer. NSAID use reduced the risk of cancer development in all the participants, but its effect was greatest in those with three genetic abnormalities.
###end p 14
###begin title 15
What Do These Findings Mean?
###end title 15
###begin p 16
###xml 138 146 <span type="species:ncbi:9606">patients</span>
###xml 327 335 <span type="species:ncbi:9606">patients</span>
###xml 390 402 <span type="species:ncbi:9606">participants</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
###xml 702 708 <span type="species:ncbi:9606">people</span>
These findings suggest that the combined measurement of 17pLOH, 9pLOH, and cellular DNA content might be a powerful way to identify those patients with Barrett's esophagus who are most likely to develop esophageal cancer. They also suggest that NSAID use is associated with a reduced risk of esophageal cancer, particularly in patients with multiple genetic abnormalities. Because very few participants developed cancer during the study, these results need confirming in more patients. Also, the ability of NSAIDs to prevent the progression of Barrett's esophagus to esophageal cancer needs testing in multicenter randomized trials; the use of the panel of abnormalities described here to identify the people with Barrett's esophagus most at risk of developing esophageal cancer should facilitate such studies.
###end p 16
###begin title 17
Additional Information.
###end title 17
###begin p 18
Please access these Web sites via the online version of this summary at .
###end p 18
###begin p 19
 information from Emory University (Atlanta, Georgia, United States) on cancer biology, including the role of tumor suppressor proteins
###end p 19
###begin p 20
###xml 29 36 <span type="species:ncbi:9606">patient</span>
US National Cancer Institute patient and physician information on  and its 
###end p 20
###begin p 21
MedlinePlus encyclopedia pages on  and 
###end p 21
###begin p 22
###xml 26 33 <span type="species:ncbi:9606">patient</span>
Cancerbackup (UK charity) patient information on 
###end p 22
###begin title 23
Introduction
###end title 23
###begin p 24
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b001">1</xref>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b004">4</xref>
###xml 611 612 611 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b005">5</xref>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b010">10</xref>
###xml 881 883 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b011">11</xref>
###xml 884 886 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b012">12</xref>
###xml 1084 1086 1084 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b013">13</xref>
###xml 1087 1089 1087 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b016">16</xref>
###xml 1268 1269 1268 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b004">4</xref>
###xml 460 468 <span type="species:ncbi:9606">patients</span>
###xml 960 968 <span type="species:ncbi:9606">patients</span>
Rapid advances in understanding the molecular pathogenesis of neoplasia have raised the possibility that molecular abnormalities may be used as "biomarkers" for cancer risk stratification and early detection as well as possible entry criteria for cancer-prevention trials [1-4]. Identification of inherited, highly penetrant mutations in some cancer-susceptibility genes is being incorporated into clinical practice as well as cancer-prevention strategies for patients with many familial cancer syndromes, including inherited breast cancer, hereditary nonpolyposis colon cancer, and adenomatous polyposis coli [5-10]. Although progress in developing predictive biomarkers from common somatic genetic abnormalities in at-risk tissues has been less striking, there is some evidence that this approach may be successful. Based on a genetic progression model for head and neck cancer [11,12], a series of retrospective, longitudinal studies have been performed on patients with the premalignant condition oral leukoplakia, resulting in potential biomarker panels for risk stratification [13-16]. Some of these biomarkers have been proposed as entry criteria for a randomized cancer-prevention trial using cyclo-oxygenase-2 and epidermal growth factor receptor inhibitors [4]. Understanding how modifiable exposures interact with the somatic genetic composition of a neoplasm will be important for individualized interventions and cancer prevention.
###end p 24
###begin p 25
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b017">17</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b018">18</xref>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b019">19</xref>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b020">20</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b021">21</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b025">25</xref>
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b026">26</xref>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b027">27</xref>
###xml 808 812 808 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 817 824 817 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A,</italic>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b028">28</xref>
###xml 937 939 937 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b040">40</xref>
###xml 1255 1257 1255 1257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b034">34</xref>
###xml 1258 1260 1258 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b041">41</xref>
###xml 1261 1263 1261 1263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b045">45</xref>
###xml 1086 1094 <span type="species:ncbi:9606">patients</span>
Barrett's esophagus (BE) is a premalignant condition that predisposes to esophageal adenocarcinoma (EA). The incidence of this cancer has risen dramatically in the United States, Western Europe, Australia, and other developed countries over the past three decades, with little sign of abating [17,18]. Unfortunately, EA is typically lethal unless detected early, having an overall survival rate of only 13.7% [19]. Endoscopic surveillance is recommended for early detection in BE [20], and there has been recent interest in the potential for cancer prevention using nonsteroidal anti-inflammatory drugs (NSAIDs) based on data from case control and cohort studies [21-25], as well as preclinical models [26,27]. Analysis of genetic progression of BE has identified abnormalities in the tumor-suppressor genes TP53 and CDKN2A, as well as DNA content abnormalities (tetraploidy and aneuploidy) as critical events in the evolution of EA [28-40]. Several prospective studies have suggested that individual somatic genetic abnormalities derived from this progression model may identify those patients with BE who are at increased risk for progression to EA, but no study has evaluated the combined contributions of genetic abnormalities for EA risk prediction [34,41-45].
###end p 25
###begin p 26
###xml 314 327 314 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53, CDKN2A,</italic>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Using data collected prospectively over a 10-y period from a long-standing cohort study of patients with BE, we investigated the role of host factors in combination with somatic genetic abnormalities in the development of EA. The aims of the study were to determine whether somatic genetic abnormalities involving TP53, CDKN2A, and DNA content were predictors of progression to EA and whether regular NSAID use modulates risk of these abnormalities for future EA.
###end p 26
###begin title 27
Methods
###end title 27
###begin title 28
Study Design
###end title 28
###begin p 29
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b003">3</xref>
###xml 279 284 <span type="species:ncbi:9606">Human</span>
###xml 652 657 <span type="species:ncbi:9606">Human</span>
This was a prospective, longitudinal study of the Seattle Barrett's Esophagus Study cohort. It constituted a phase 4 study according to the National Cancer Institute's Early Detection Research Network classification [3]. The Seattle Barrett's Esophagus Study was approved by the Human Subjects Division of the University of Washington in 1983 and was renewed annually thereafter with reciprocity from the Institutional Review Board of the Fred Hutchinson Cancer Research Center from 1993 to 2001. Since 2001, the study has been approved annually by the Institutional Review Board of the Fred Hutchinson Cancer Research Center with reciprocity from the Human Subjects Division of the University of Washington.
###end p 29
###begin title 30
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
Participants
###end title 30
###begin p 31
###xml 522 529 522 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040067-t001">Table 1</xref>
###xml 1244 1246 1244 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b044">44</xref>
###xml 29 41 <span type="species:ncbi:9606">participants</span>
###xml 317 329 <span type="species:ncbi:9606">participants</span>
###xml 469 481 <span type="species:ncbi:9606">participants</span>
###xml 751 759 <span type="species:ncbi:9606">patients</span>
###xml 793 801 <span type="species:ncbi:9606">patients</span>
###xml 820 828 <span type="species:ncbi:9606">patients</span>
###xml 1034 1041 <span type="species:ncbi:9606">patient</span>
Two hundred and seventy-four participants were eligible as defined by a diagnosis of metaplastic columnar epithelium with intestinal metaplasia in esophageal biopsies, the absence of esophageal malignancy at or prior to baseline endoscopy, and having had at least one follow-up endoscopy. Two hundred and forty-three participants had sufficient tissue for flow cytometry, mutation, and LOH analysis in the same DNA samples and represented the final study cohort. Study participants entered surveillance from 1983 to 1999 (Table 1). The baseline endoscopy was defined as the first endoscopy from 5 January 1995 to 2 December 1999. Since this is a long-standing cohort, we assessed the enrollment-time effect by performing statistical analyses with all patients, and also with the subset of 211 patients, excluding the 32 patients who entered the cohort before 1990, and found no change in the conclusions of the study. This study was conducted at a specialty research and referral center, and thus our cohort is considered a high-risk patient population. We included all cancers that developed subsequent to the baseline evaluation so that accurate risk-stratification models could be developed based on findings at a single baseline endoscopy [44].
###end p 31
###begin p 32
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b046">46</xref>
###xml 995 997 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b047">47</xref>
###xml 1105 1106 1105 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 13 25 <span type="species:ncbi:9606">participants</span>
###xml 117 125 <span type="species:ncbi:9606">Patients</span>
###xml 379 387 <span type="species:ncbi:9606">patients</span>
###xml 503 511 <span type="species:ncbi:9606">patients</span>
###xml 659 671 <span type="species:ncbi:9606">participants</span>
###xml 1013 1021 <span type="species:ncbi:9606">patients</span>
###xml 1156 1168 <span type="species:ncbi:9606">Participants</span>
All research participants were counseled concerning the risks and benefits of endsocopic biopsy surveillance for BE. Patients with high-grade dysplasia (HGD) were also counseled concerning the risks and benefits of esophagectomy and endoscopic therapies. Endoscopic biopsy protocols used in the Seattle Barrett's Esophagus Study have been published previously [46]. Briefly, all patients had one biopsy evaluated for biomarkers every 2 cm in the Barrett's segment regardless of histologic diagnosis. In patients without HGD, four-quadrant biopsies were obtained for histologic evaluation every 2 cm in the Barrett's segment. If, after fully informed consent, participants with HGD opted for endoscopic biopsy surveillance reserving intervention for cancer if detected, they were evaluated by an intensive protocol of four-quadrant biopsies every 1 cm in the Barrett's epithelium at closely timed intervals for 4 mo, after which time endoscopies were typically repeated approximately every 6 mo [47]. Exclusion of patients who were diagnosed with EA that developed within 4 mo of their baseline procedure (n = 4) did not alter the conclusions of the study. Participants with maximum baseline diagnosis of HGD had an average of 7.3 endoscopies (median = 6.5, range 2-18), compared to those with less HGD at baseline, who had an average of 4.8 endoscopies (median = 4, range 2-20).
###end p 32
###begin p 33
###xml 114 121 114 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040067-t001">Table 1</xref>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b048">48</xref>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b051">51</xref>
###xml 376 377 376 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 397 398 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 427 428 427 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 445 446 445 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 500 502 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b043">43</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b052">52</xref>
###xml 286 298 <span type="species:ncbi:9606">participants</span>
###xml 732 744 <span type="species:ncbi:9606">Participants</span>
###xml 781 788 <span type="species:ncbi:9606">patient</span>
The cohort is typical for gender, age, and Barrett's segment length compared to other specialty research centers (Table 1) [48-51]. The cohort included 189 males and 54 females with a mean age of 62 y (median = 64 y, range 30-87 y) at entry into the study. This cohort was comprised of participants with maximum baseline histologic diagnoses including negative for dysplasia (n = 67), indefinite (n = 78), low-grade dysplasia (n = 48), and HGD (n = 50) using previously published pathology criteria [43,52]. The mean Barrett's segment length, defined by total centimeters between the ora serrata and the distal end of the tubular esophagus proximal to the flattening of the gastric folds, was 5.6 cm (median = 5 cm, range 0-20 cm). Participants were followed for a total of 17,139 patient-months with a mean of 71 mo (median = 80.5 mo, range 2.3-130.8 mo).
###end p 33
###begin title 34
Endoscopy and Biopsy
###end title 34
###begin p 35
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b043">43</xref>
###xml 104 105 104 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 248 249 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 451 464 451 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53, CDKN2A,</italic>
###xml 614 624 614 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53, TP53</italic>
###xml 720 732 720 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A (p16)</italic>
###xml 740 746 740 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 773 779 773 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 68 80 <span type="species:ncbi:9606">Participants</span>
###xml 894 905 <span type="species:ncbi:9606">participant</span>
###xml 914 925 <span type="species:ncbi:9606">participant</span>
Endoscopy and biopsy were performed using a standard protocol [43]. Participants with a history of HGD (n = 50) had histologic evaluation of four-quadrant biopsies at 1-cm intervals in the Barrett's segment, whereas those without a history of HGD (n = 193) had histologic analysis of four-quadrant biopsies at 2-cm intervals. Histologic analyses were evaluated in biopsies obtained at the baseline evaluation and at all follow-up endoscopies, whereas TP53, CDKN2A, and DNA content analyses were evaluated at a single baseline endoscopy. For each baseline endoscopy, samples were characterized for 17p LOH spanning TP53, TP53 mutations, DNA content abnormalities including tetraploidy and aneuploidy, 9p LOH spanning the CDKN2A (p16) locus, CDKN2A promoter methylation, and CDKN2A mutation in one biopsy every 2 cm in the Barrett's segment (average = 3.2, range 1-11 biopsies analyzed per study participant). For a participant to be counted as having a molecular abnormality at baseline, the abnormality must have been detected in more than one flow-purified DNA fraction or in a single sample that has been confirmed in a second, independent reaction.
###end p 35
###begin title 36
Flow Cytometry
###end title 36
###begin p 37
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b043">43</xref>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b045">45</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b053">53</xref>
Biopsies were processed by DNA content (DAPI) and Ki67/DNA content flow cytometry to determine 4N fraction and ploidy, and to purify proliferating cells using previously validated techniques [43,45,53]. Flow-purified fractions are defined as Ki67-positive (proliferating) 2N, 4N, increased 4N/tetraploid (cells with DNA content between 3.85 and 4.10N that comprise >6% of the total cells), and aneuploid populations (distinct DNA content peak representing >2.5% of cells). Cell-cycle analysis was performed on 1,569 flow-purified fractions with a median of 6.5 (range 1-29) cell-cycle fractions depending on Barrett's segment length.
###end p 37
###begin title 38
DNA Extraction, Whole-Genome Amplification and LOH Analysis
###end title 38
###begin p 39
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b053">53</xref>
###xml 506 508 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b034">34</xref>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b044">44</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b053">53</xref>
###xml 627 631 627 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 643 644 643 644 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
###xml 643 644 643 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>n</sub></italic>
###xml 669 673 669 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 678 679 678 679 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sub>
###xml 678 679 678 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>n</sub></italic>
###xml 1084 1087 1084 1087 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOH</sup>
###xml 1130 1134 1126 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1138 1144 1134 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 1146 1148 1142 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b034">34</xref>
###xml 1149 1151 1145 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b044">44</xref>
###xml 1152 1154 1148 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b053">53</xref>
###xml 1348 1352 1344 1348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1356 1363 1352 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A.</italic>
###xml 1452 1454 1448 1450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b034">34</xref>
###xml 1455 1457 1451 1453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b044">44</xref>
###xml 363 374 <span type="species:ncbi:9606">participant</span>
###xml 1380 1392 <span type="species:ncbi:9606">participants</span>
###xml 1411 1419 <span type="species:ncbi:9606">patients</span>
DNA was extracted from flow-purified cell populations using either standard phenol/chloroform or the Puregene DNA Isolation Kit as recommended by the manufacturer (Gentra Systems, Minneapolis, Minnesota, United States). Whole-genome amplification using primer extension preamplification was performed with each sorted fraction and three constitutive controls per participant [53]. LOH data was obtained from 1,331 and 1,284 flow-purified fractions at 17p and 9p loci, respectively, as detailed previously [34,44,53]. Thirteen microsatellite loci were evaluated, including the 17p loci D17S1298 (3.87 Mbp), D17S1537 (6.10 Mbp), TP53-ALU (AAAAT)n in intron 1 (7.77 Mbp), TP53 (CA)n (7.77 Mbp), D17S786 (9.01 Mbp), D17S974 (10.72 Mbp), D17S1303 (11.06 Mbp), and Chromosome 9p loci D9S2169 (5.19 Mbp), D9S935 (5.19 Mbp), D9S925 (18.28 Mbp), D9S932 (24.43 Mbp), D9S1121 (25.39 Mbp), and D9S1118 (31.92 Mbp). Physical map locations were determined from the University of California, Santa Cruz (Santa Cruz, California, United States) version hg16 July 2003 assembly (). LOH was defined as QLOH </= 0.4 or >/= 2.5 for loss which spanned TP53 or CDKN2A [34,44,53]. For convenience, we used the nomenclature of 17p LOH and 9p LOH to describe LOH events spanning these genes. LOH was not scored for rare telomeric or centomeric loss events that did not span TP53 or CDKN2A. 17p LOH for all participants and 9p LOH in HGD patients have been previously published [34,44].
###end p 39
###begin title 40
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
CDKN2A Promoter Methylation Analysis
###end title 40
###begin p 41
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 167 168 167 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 196 202 196 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b031">31</xref>
###xml 762 764 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b054">54</xref>
###xml 765 767 765 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b055">55</xref>
###xml 1111 1113 1111 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b031">31</xref>
###xml 1189 1191 1189 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b031">31</xref>
###xml 138 150 <span type="species:ncbi:9606">participants</span>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
###xml 406 413 <span type="species:ncbi:9606">patient</span>
###xml 458 465 <span type="species:ncbi:9606">patient</span>
###xml 770 775 <span type="species:ncbi:9606">Human</span>
###xml 1150 1158 <span type="species:ncbi:9606">patients</span>
Genomic DNA from flow-purified Barrett's epithelium was evaluated for CDKN2A promoter methylation in 175 flow-purified fractions from 121 participants. Only a subset (n = 121) of the patients had CDKN2A methylation tested because the bisulfite treatment assays used required large amounts of DNA, and the DNA from our flow-purified fractions was insufficient for all molecular assays to be performed. This patient subset was representative of the entire 243-patient cohort with no statistically significant difference in follow-up time, sex, age, segment length, and cancer outcome between the methylation-assayed group and the non-assayed group. DNA was bisulfite treated and methylation-specific PCR was performed with modifications as detailed previously [31,54,55]. Human genomic DNA treated in vitro with Sss I methyltransferase (New England Biolabs, Beverly, Massachusetts, United States) was used as the methylated control. In a subset of cases, promoter methylation was determined and/or verified by directly sequencing PCR products of bisulfite-treated genomic DNA using published primers and methods [31]. Methylation data from a subset of patients has been previously reported [31].
###end p 41
###begin title 42
DNA Sequencing
###end title 42
###begin p 43
###xml 521 525 521 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b056">56</xref>
###xml 622 626 622 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b056">56</xref>
###xml 715 719 715 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 840 846 840 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 983 985 983 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b031">31</xref>
###xml 272 283 <span type="species:ncbi:9606">participant</span>
###xml 642 650 <span type="species:ncbi:9606">patients</span>
Genomic or primer extension preamplification DNA was sequenced using either BigDye or BigDyeV3 Terminator cycle sequencing (Applied Biosystems, Foster City, California, United States) on either an ABI 377, ABI 3730, or ABI 3700 DNA sequencer. Wild-type sequences for each participant were confirmed using constitutive samples. All mutations were confirmed by at least two independent PCR and sequencing reactions and, in cases of ambiguity, by direct sequencing of genomic DNA. Evaluation of mutation of exons 5-9 of the TP53 gene was performed on 1,118 flow-purified fractions under conditions described previously [56]. TP53 mutations from patients with HGD were reported by Prevo et al. [56], and additional new TP53 mutations not previously reported are available from the corresponding author (PCG). Mutation analysis of exon 2 of the CDKN2A gene was performed in 1,109 flow-purified fractions, detailed by Paulson 2006 (unpublished data) and with methods described previously [31].
###end p 43
###begin title 44
Use of Aspirin and Other NSAIDs
###end title 44
###begin p 45
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b025">25</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b025">25</xref>
###xml 706 708 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b025">25</xref>
###xml 887 888 885 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 959 960 957 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 119 131 <span type="species:ncbi:9606">participants</span>
###xml 711 719 <span type="species:ncbi:9606">Patients</span>
###xml 762 770 <span type="species:ncbi:9606">patients</span>
Questionnaires and methods for determining host variables were as described previously [25] and were available for 241 participants. Use of aspirin and other NSAIDs in the current study was defined in the same way as NSAID use, including NSAID use in follow-up, as described in Vaughan et al. [25]. Briefly, duration and frequency of regular aspirin and NSAID use were assessed, with "regular" defined by use at least once per week for >/=6 mo. The NSAID variable took into account changes in aspirin and NSAID medication use during the follow-up period. It has been shown previously that there are no significant differences between the protective associations of aspirin and other NSAIDs in this cohort [25]. Patients were classified as being users (including patients who were regular aspirin or other NSAID users within 1 y of the baseline interview or at any time during follow-up, n = 157), or nonusers (former users or those who had never used NSAIDs, n = 84).
###end p 45
###begin title 46
Statistical Analysis
###end title 46
###begin p 47
###xml 470 477 470 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040067-t002">Table 2</xref>
###xml 656 663 656 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040067-t003">Table 3</xref>
###xml 878 885 878 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040067-t004">Table 4</xref>
###xml 1313 1322 1313 1322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040067-g001">Figures 1</xref>
###xml 1327 1328 1327 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040067-g002">2</xref>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
###xml 379 387 <span type="species:ncbi:9606">patients</span>
###xml 766 774 <span type="species:ncbi:9606">patients</span>
###xml 846 854 <span type="species:ncbi:9606">patients</span>
We sought to evaluate the extent to which specific tissue-based, mechanistically derived molecular markers, both alone and in combination, predict risk of progression to EA in patients with BE. The analytic approach is summarized as follows. (1) Univariate Cox proportional hazard analyses (not adjusted for host variables or other markers) were used to determine the EA risk of patients with each marker, measured at baseline at 2-, 6-, and 10-y follow-up time points (Table 2). (2) Stepwise multivariate Cox regression was used to select, from among all of the available molecular markers, a subset which independently contributes to EA risk prediction (Table 3). (3) Cumulative EA incidence and relative risk (RR) of progression to EA at 10 y were calculated for patients with different numbers of the selected markers at baseline relative to patients with no abnormalities (Table 4). To determine the contribution of known or suspected nongenetic host factors to EA risk prediction, we incorporated these host factors together with all molecular markers in a multivariate Cox model. Only NSAID use showed significant independent prediction in combination with molecular markers in this multivariate model. The predictive ability of the selected molecular markers was evaluated among NSAID users and nonusers (Figures 1 and 2).
###end p 47
###begin p 48
###xml 101 105 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 153 159 153 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 182 188 182 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 299 305 299 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 722 723 722 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1212 1213 1210 1211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1249 1257 1247 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040067-g002">Figure 2</xref>
###xml 1299 1301 1297 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b057">57</xref>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
###xml 286 297 <span type="species:ncbi:9606">participant</span>
###xml 400 408 <span type="species:ncbi:9606">patients</span>
Two hundred and forty-three patients had informative data for all of the molecular markers (17p LOH, TP53 mutation, tetraploidy, aneuploidy, 9p LOH, and CDKN2A mutation). Except for CDKN2A methylation, all markers in the analysis were binary variables coded as 0 (no), 1 (yes) for each participant. CDKN2A methylation status was coded as yes, no, or no data in the statistical model because only 121 patients had sufficient quantity of DNA to be evaluated for this marker. In the Cox regression models for molecular marker selection, the statistical significance levels used in the initial process of stepwise selection for variable entry and removing were 0.25 and 0.15, respectively. Based on initial selection results, p = 0.05 was used as the significance threshold for the final selection (second Cox model). Association relationship among binary markers was also assessed using coefficient Phi. The Kaplan-Meier method was used to estimate the probability of EA in different stratified groups. The Gehan-Wilcoxon test was used to test differences in the cancer incidence curves. The Grambsch-Therneau test was used to examine the significance of a change in RR ratio over time for all markers. We adjusted p-values for multiple comparisons in Figure 2 using the Benjamini and Hochberg method [57]. All of the analyses were performed with Statistical Analysis System (SAS) software Version 9.0; (SAS Institute, ).
###end p 48
###begin title 49
Results
###end title 49
###begin title 50
Univariate Analysis of LOH, Mutation, Methylation, Tetraploidy, and Aneuploidy for EA Risk Prediction
###end title 50
###begin p 51
###xml 101 108 101 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040067-t001">Table 1</xref>
###xml 330 337 330 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040067-t002">Table 2</xref>
###xml 546 553 546 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040067-t002">Table 2</xref>
###xml 577 584 577 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040067-t002">Table 2</xref>
###xml 891 897 891 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 939 940 939 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 953 959 953 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 999 1000 999 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1107 1108 1107 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1169 1170 1169 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1381 1382 1381 1382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1600 1601 1600 1601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 31 43 <span type="species:ncbi:9606">participants</span>
###xml 156 168 <span type="species:ncbi:9606">participants</span>
###xml 197 209 <span type="species:ncbi:9606">participants</span>
###xml 374 382 <span type="species:ncbi:9606">patients</span>
###xml 790 797 <span type="species:ncbi:9606">patient</span>
The cohort characteristics for participants used for molecular and DNA content analysis are shown in Table 1. During the follow-up period of this study, 34 participants developed EA. The number of participants with each genetic abnormality at baseline and the cumulative number who developed cancer at 2, 6, and 10 y are shown in Table 2. The risk of EA during follow-up in patients with each molecular and DNA content abnormality was assessed with univariate analysis using Cox regression models (2, 6, and 10 y presented to show general trend, Table 2). The RRs presented in Table 2 were not adjusted for host variables, but the significance of the results does not change when such adjustments are performed. At 10 y, each molecular and DNA content abnormality, when analyzed alone in a patient at baseline, made a significant contribution to prediction of EA risk, with the exception of CDKN2A mutation (10-y RR = 1.8; 95% CI 0.8-4.1, p = 0.13) and CDKN2A methylation (RR = 2.1; 95% CI 0.8-4.1, p = 0.09). For example, the univariate RRs ranged from a high for 17p LOH (10-y RR = 10.6; 95% CI 5.2-21.3, p < 0.001) to that for 9p LOH (10-y RR = 2.6; 95% CI 1.1-6.0, p = 0.03). Although RRs at intermediate time points may be unstable owing to small numbers, 9p LOH had a higher RR at early follow-up intervals. The RR in univariate analysis for 9p LOH was 8.9 (95% CI 1.2-67.9, p = 0.04) at 2-y follow-up, but decreased to RR = 2.6 by 10 y. With the current dataset, 9p LOH was the only abnormality that showed a statistically significant change in RR over time (nonproportional hazard over time, p = 0.004, Grambsch-Therneau test for global trend at 10 y).
###end p 51
###begin title 52
Comprehensive Analysis of Relationships among the Multiple Molecular Abnormalities for EA Risk Prediction
###end title 52
###begin p 53
###xml 384 388 384 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 447 451 447 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 812 813 812 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 823 829 823 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 941 942 941 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 952 958 952 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 1188 1195 1188 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040067-t003">Table 3</xref>
###xml 1326 1330 1324 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1555 1559 1547 1551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 2006 2013 1998 2005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040067-t003">Table 3</xref>
To determine a set of biomarkers that are independent predictors of EA risk, baseline molecular markers were evaluated using multivariate Cox models with backward and forward stepwise selection. Starting with all molecular abnormalities for selection, 17p LOH was the most significant abnormality selected by the statistical model, and remained a strong predictor when accounting for TP53 mutation status in a step-wise analysis process. Although TP53 mutation was highly significant in univariate analysis, it became nonsignificant for EA risk prediction when 17p LOH was included in the model. Tetraploidy was the next selected marker, followed by aneuploidy. Finally, 9p LOH improved the model for risk prediction significantly in combination with 17p LOH and DNA content abnormalities (likelihood ratio test p = 0.03). CDKN2A methylation provided marginal additional risk but was not statistically significant in the multivariate model (p = 0.28). CDKN2A mutation did not provide significant additional contribution to EA risk prediction. The final selected molecular markers that independently contributed to EA risk prediction included 17p LOH, tetraploidy, aneuploidy, and 9p LOH (Table 3). To further evaluate the associations among the markers, we calculated the association coefficient (Phi) for all binary markers. TP53 mutation showed strong association with 17p LOH (Phi = 0.63) and aneuploidy (Phi = 0.56). 17p LOH is also strongly associated with aneuploidy (Phi = 0.56). No other strong associations were observed by this method. Although TP53 mutation was significantly related to EA risk in univariate analysis, it was strongly associated with 17p LOH and aneuploidy, which may explain why it was not retained in the model selection. The adjusted RRs for future EA at 10 y, using the final selected model with 17p LOH, tetraploidy, aneuploidy, and 9p LOH, were RR = 5.4 (95% CI 2.5-12.0), RR = 2.9 (95% CI 1.4-5.9), RR = 3.4 (95% CI 1.6-7.1), and RR = 2.4 (95% CI 1.0-5.5), respectively (Table 3).
###end p 53
###begin title 54
Effect of Combinations of Selected Panel Abnormalities on Cumulative EA Incidence
###end title 54
###begin p 55
###xml 349 356 349 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040067-t004">Table 4</xref>
###xml 798 807 798 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040067-g001">Figures 1</xref>
###xml 812 813 812 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040067-g002">2</xref>
###xml 815 822 815 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040067-t004">Table 4</xref>
###xml 1600 1601 1600 1601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1995 1996 1995 1996 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 11 22 <span type="species:ncbi:9606">participant</span>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
###xml 286 298 <span type="species:ncbi:9606">participants</span>
###xml 482 494 <span type="species:ncbi:9606">participants</span>
###xml 831 843 <span type="species:ncbi:9606">participants</span>
###xml 996 1008 <span type="species:ncbi:9606">participants</span>
###xml 1209 1221 <span type="species:ncbi:9606">participants</span>
###xml 1314 1326 <span type="species:ncbi:9606">Participants</span>
###xml 1529 1537 <span type="species:ncbi:9606">patients</span>
###xml 1612 1624 <span type="species:ncbi:9606">Participants</span>
###xml 1873 1881 <span type="species:ncbi:9606">patients</span>
###xml 2091 2099 <span type="species:ncbi:9606">patients</span>
Each study participant had the potential to have any combination of selected panel abnormalities at baseline. Stratification by all possible combinations of the selected abnormalities was limited by an inadequate number of patients for analysis in some strata, and we therefore grouped participants based on the number of abnormalities at baseline. Table 4 lists the cumulative EA incidence at 2, 6, and 10 y, and the RR at maximum follow-up (10 y) for future development of EA for participants with no panel abnormalities, a single abnormality (either 17p LOH, any DNA content abnormality, or 9p LOH), any two selected abnormalities, or all three selected abnormalities at baseline. Tetraploidy and aneuploidy are two measures of DNA content and were treated as a single variable in this section (Figures 1 and 2; Table 4). Study participants with no baseline abnormalities (85/243) remained cancer free to almost 8 y (95 mo) and had a relatively low 10-y cumulative cancer incidence of 12%. In participants with only a single baseline abnormality (104/243), the 6-y EA incidence was 5.65%, with an overall 10-y EA incidence of 19.88%. It is of note that 9p LOH was the single abnormality in 98/104 of those participants, indicating that it was rare for 17p LOH or a DNA content abnormality to be detected alone. Participants with two abnormalities detected at baseline (32/243) had increasing cumulative EA incidence of 16.83%, 28.4%, and 35.56% at 2, 6, and 10 y, respectively, showing a significantly higher EA risk than for patients with no abnormalities at baseline (RR = 9.0; 95% CI 2.4-33.3, p < 0.001). Participants (22/243) with all three abnormalities (17p LOH, DNA content abnormality, and 9p LOH) had EA incidence rates of 40.2% and 79.12% at 2 and 6 y, respectively. Owing to sample size, the EA incidence rate at the 10-y time point was not estimated. These patients had the highest risk of cancer relative to those with a no baseline abnormalities (RR = 38.7; 95% CI 10.8-135.5, p < 0.001). Of these cancer cases, 80% occurred within 36 mo, and all cancers that developed in patients with three baseline abnormalities did so within a 55-mo follow-up period.
###end p 55
###begin title 56
###xml 54 66 <span type="species:ncbi:9606">Participants</span>
Association of NSAID Use with Reduction of EA Risk in Participants with 17p LOH, DNA Content Tetraploidy and Aneuploidy, and 9p LOH
###end title 56
###begin p 57
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b024">24</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b058">58</xref>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b067">67</xref>
###xml 729 730 729 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1109 1117 1109 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040067-g001">Figure 1</xref>
###xml 1194 1195 1194 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1286 1287 1286 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1309 1310 1309 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1320 1328 1320 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040067-g001">Figure 1</xref>
###xml 1468 1469 1468 1469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1627 1635 1627 1635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040067-g001">Figure 1</xref>
###xml 1738 1745 1738 1745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040067-t004">Table 4</xref>
###xml 1840 1841 1840 1841 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1053 1065 <span type="species:ncbi:9606">participants</span>
###xml 1162 1170 <span type="species:ncbi:9606">patients</span>
###xml 1338 1346 <span type="species:ncbi:9606">patients</span>
###xml 1642 1654 <span type="species:ncbi:9606">participants</span>
Multiple nongenetic host factors and demographic variables have been previously suggested as potential modifiers of EA progression including age, gender, waist-to-hip ratio, smoking status, segment length, and NSAID use [24,58-67]. To determine the host variables that provide independent prediction for EA when combined with molecular markers, we incorporated these nongenetic host factors with all molecular markers into a new Cox model for variable selection. The selected independent variables were 17p LOH, DNA content abnormalities (tetraploidy and aneuploidy), 9p LOH, and NSAID use. In combination with the selected molecular abnormalities, NSAID use was associated with a statistically significant reduction of EA risk (p < 0.001). Thus, NSAID use was evaluated as a potential modulator of cancer risk in combination with selected genetic abnormalities. For a given selected molecular marker, Kaplan-Meier analysis showed that NSAID use during follow-up provided a significant association with protection against development of EA, relative to participants who were NSAID nonusers (former or never) (Figure 1). This protective effect was significant in patients with baseline 17p LOH (p = 0.004, Gehan-Wilcoxon test), DNA content abnormalities (tetraploidy and/or aneuploidy) (p = 0.01), and 9p LOH (p <0.001) (Figure 1A-C). For patients with more than one panel abnormality at baseline, NSAID use was associated with a significant reduction in EA incidence (p = 0.001): NSAID nonusers had an observed cumulative EA risk of 68%, compared to 30% for NSAID users at 6 y, and 79% compared to 30% for NSAID users at 10 y (Figure 1D). In participants with either no abnormalities or one abnormality at baseline (predominantly 9p LOH, Table 4), cancer risk was low, and the protective effect of NSAIDs for future EA was not significant (p = 0.28 at 10-y follow-up).
###end p 57
###begin title 58
EA Incidence in NSAID Nonusers and NSAID Users Stratified by Combinations of Baseline Abnormalities
###end title 58
###begin p 59
###xml 140 148 140 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040067-g002">Figure 2</xref>
###xml 183 191 183 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040067-g002">Figure 2</xref>
###xml 194 195 194 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 219 227 219 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040067-g002">Figure 2</xref>
###xml 230 231 230 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 425 426 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 611 612 611 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 637 638 637 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 665 666 665 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 693 694 693 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 774 776 774 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b057">57</xref>
###xml 779 787 779 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040067-g002">Figure 2</xref>
###xml 965 973 965 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040067-g002">Figure 2</xref>
###xml 1137 1138 1137 1138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1148 1149 1148 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1163 1164 1163 1164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1358 1359 1358 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1372 1373 1372 1373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 24 36 <span type="species:ncbi:9606">participants</span>
###xml 854 866 <span type="species:ncbi:9606">participants</span>
###xml 925 937 <span type="species:ncbi:9606">Participants</span>
Cancer incidence of all participants based on the overall number of select panel abnormalities at baseline is shown in Kaplan-Meier curves (Figure 2A). When comparing NSAID nonusers (Figure 2B, n = 84) and NSAID users (Figure 2C, n = 157) within all categories (zero, one, two, or three abnormalities at baseline), there was a strong significant trend toward EA risk reduction in the NSAID user's group (Mantel-Haenszel test p = 0.01). NSAID nonusers with two or three abnormalities at baseline had a highly significant increased EA incidence compared to NSAID nonusers with zero or one lesion (two versus zero p < 0.001; two versus one p <0.001; three versus zero p < 0.001; three versus one p < 0.001; adjusted for multiple comparisons with Benjamini and Hochberg method [57] [Figure 2B]). All other comparisons for NSAID nonusers, for example between participants with two versus three abnormalities, were nonsignificant. Participants who used NSAIDs regularly (Figure 2C) and had all three abnormalities at baseline had a significantly increased cumulative EA incidence compared to NSAID users with zero, one, and two abnormalities (p < 0.001, p < 0.001, and p = 0.045, respectively). NSAID users with two baseline abnormalities had a significant or marginally significant increased cancer incidence relative to NSAID users with zero or one abnormality (p = 0.013 and p = 0.07, respectively).
###end p 59
###begin title 60
Discussion
###end title 60
###begin p 61
###xml 295 308 295 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53, CDKN2A,</italic>
###xml 1083 1085 1083 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b041">41</xref>
###xml 1086 1088 1086 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b042">42</xref>
###xml 1089 1091 1089 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b068">68</xref>
###xml 1092 1094 1092 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b069">69</xref>
###xml 1483 1487 1483 1487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1522 1524 1522 1524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b041">41</xref>
###xml 1525 1527 1525 1527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b042">42</xref>
###xml 1528 1530 1528 1530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b070">70</xref>
###xml 1683 1687 1683 1687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1692 1698 1692 1698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 717 725 <span type="species:ncbi:9606">patients</span>
###xml 1286 1293 <span type="species:ncbi:9606">patient</span>
###xml 1574 1582 <span type="species:ncbi:9606">patients</span>
###xml 1604 1609 <span type="species:ncbi:9606">human</span>
This investigation reports the results of a prospective cohort study of mechanistic-based genetic abnormalities evaluated as predictors of EA and demonstrates the modulating effect of NSAIDs on EA risk in patients with BE. We hypothesized that a panel of somatic genetic abnormalities involving TP53, CDKN2A, and DNA content could improve prediction of progression to EA and that NSAID use may modulate EA risk. In this longitudinal study spanning more than a decade, we showed that a combination of 17p LOH, 9p LOH, and DNA content tetraploidy and aneuploidy provide significant, independent EA risk prediction. NSAID use is associated with reduction of EA risk, and the protective effect was highly significant for patients who have multiple high-risk molecular abnormalities at baseline. These analyses include 34 EA endpoints, which is second only to our previous 15-y report of histology and flow cytometry (42 EAs) and substantially larger than most other longitudinal studies of biomarkers in BE from other centers, which have typically reported 12 or fewer incident cancers [41,42,68,69]. This prospective study has been conducted in a single center with a high-risk cohort; studies in other centers will be required to determine whether our results can be generalized to other patient populations and to validate the results for clinical application. Our results are consistent, however, with previous longitudinal studies of single biomarkers from other centers, including TP53 abnormalities and flow cytometry [41,42,70]. To our knowledge, no previous studies in patients with BE or any other human premalignant condition have prospectively evaluated the contributions of TP53 and CDKN2A gene inactivation (methylation, mutation, and LOH) and DNA content abnormalities in combination with candidate interventions to assess their potential utility as biomarkers for future cancer risk and cancer prevention.
###end p 61
###begin p 62
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 378 379 378 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b001">1</xref>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b071">71</xref>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b075">75</xref>
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b076">76</xref>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b077">77</xref>
###xml 635 639 635 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 685 691 685 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 707 709 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b078">78</xref>
###xml 836 838 836 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b079">79</xref>
###xml 933 941 933 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(CDKN2A)</italic>
###xml 979 984 979 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53,</italic>
###xml 307 312 <span type="species:ncbi:9606">human</span>
The mechanisms by which TP53 and CDKN2A regulate the cell cycle under normal and abnormal conditions have been investigated extensively in elegant molecular studies in vitro and in model organisms. Perturbations of these genes and the pathways in which they act have profound, mechanistic associations with human cancer based upon evidence accumulated in numerous laboratories [1,71-75]. In BE, neoplastic progression is characterized by clonal evolution in which genetic instability generates variants on which natural selection acts, resulting in waves of clonal expansion, generation of new variants, and further selection [76,77]. TP53 abnormalities typically arise in clones with CDKN2A abnormalities [78], creating a condition permissive for clonal variants, including tetraploid and aneuploid populations, to survive and expand [79]. Thus, the abnormalities in this biomarker panel assess viable clones that undergo expansion (CDKN2A) and survive chromosomal instability (TP53, DNA content). Assessment of multiple stages of clonal evolution may be the basis for improved risk stratification compared to single biomarkers.
###end p 62
###begin p 63
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 144 150 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b028">28</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b029">29</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b034">34</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b080">80</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b082">82</xref>
###xml 294 298 294 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b041">41</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b070">70</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b083">83</xref>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b085">85</xref>
###xml 409 413 409 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b029">29</xref>
###xml 798 802 798 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 807 814 807 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A.</italic>
###xml 917 921 917 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIC1</italic>
###xml 933 935 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b086">86</xref>
###xml 944 947 944 947 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARF</sup>
###xml 941 947 941 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>ARF</sup></italic>
###xml 956 958 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b072">72</xref>
###xml 959 961 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b087">87</xref>
###xml 1066 1070 1066 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1075 1082 1075 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A.</italic>
###xml 1241 1247 1241 1247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(TP53)</italic>
###xml 1349 1351 1349 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b088">88</xref>
###xml 1487 1493 1487 1493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 1529 1535 1529 1535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 1699 1701 1699 1701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b076">76</xref>
###xml 1702 1704 1702 1704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b077">77</xref>
###xml 1735 1741 1735 1741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
We simultaneously measured DNA content abnormalities (tetraploidy and aneuploidy), inactivation of TP53 (mutation and LOH), and inactivation of CDKN2A (mutation, methylation, and LOH), all of which have been shown to be mechanistically related to neoplastic progression in BE [28,29,34,80-82]. TP53 abnormalities have been shown in numerous studies to be predictive of EA [41,70,83-85]. In the present study, TP53 mutations were strongly associated with 17p LOH and aneuploidy and were not selected in the multivariate analysis. Selection of LOH over methylation or mutation in the Cox model could occur because LOH is a common manifestation of the chromosomal instability that is characteristic of neoplastic progression in BE [29]. LOH could also be selected as the "second hit" for inactivating TP53 and CDKN2A. Alternatively, LOH events often span large chromosomal regions that could include other genes such as HIC1 (17p13.3) [86] and p14ARF (9p21) [72,87] that may confer additional selective advantages over mutational or methylation events that affect only TP53 and CDKN2A. Recently, Maley et al. reported that clonal diversity measures derived from evolutionary biology retained significant independent EA risk prediction with 17p (TP53) LOH and abnormal ploidy, but 9p LOH became nonsignificant when incorporating evolutionary variables [88]. The nonproportional hazard varying with time that we found for 9p LOH in the present study may reflect the genetic background of the CDKN2A clone. For example, expansion of a CDKN2A abnormal clone that is otherwise genetically stable may homogenize the neoplasm, minimizing diversity on which natural selection might act to promote progression [76,77]. In contrast, expansion of a CDKN2A abnormal clone predisposed to genetic instability through either environmental or somatic genetic factors would result in increased diversity that could promote progression.
###end p 63
###begin p 64
###xml 357 364 357 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040067-t002">Table 2</xref>
###xml 472 480 <span type="species:ncbi:9606">patients</span>
###xml 591 599 <span type="species:ncbi:9606">patients</span>
Although this study had a large number of EA endpoints for published studies of BE, the number of cancers was relatively small compared to studies in breast and colon, for example. Therefore, estimates of RR over time showing the 9p LOH nonproportional hazard over time need to be further investigated in future studies. In addition, RR for EA presented in Table 2 at intermediate follow-up times should be treated with caution. We do not recommend that clinicians manage patients on these data alone. Within the BE research field, there is a paucity of data concerning progression to EA in patients with different molecular abnormalities. We present the intermediate time points to inform design of future intervention and multicenter studies, while maintaining statistical rigor in our analyses.
###end p 64
###begin p 65
###xml 142 157 142 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(BRCA1, BRCA2),</italic>
###xml 182 188 182 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(APC),</italic>
###xml 419 420 419 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b005">5</xref>
###xml 421 422 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b006">6</xref>
###xml 423 424 423 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b009">9</xref>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b010">10</xref>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b089">89</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b091">91</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b011">11</xref>
###xml 761 763 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b013">13</xref>
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b014">14</xref>
###xml 767 769 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b092">92</xref>
###xml 770 773 770 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b104">104</xref>
###xml 776 789 776 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53, CDKN2A,</italic>
###xml 1031 1032 1031 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b001">1</xref>
###xml 1033 1035 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b071">71</xref>
###xml 1036 1038 1036 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b073">73</xref>
###xml 1310 1312 1310 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b013">13</xref>
###xml 1313 1315 1313 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b016">16</xref>
###xml 1470 1473 1470 1473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1599 1601 1599 1601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b013">13</xref>
###xml 1221 1229 <span type="species:ncbi:9606">patients</span>
###xml 1362 1369 <span type="species:ncbi:9606">patient</span>
###xml 1565 1573 <span type="species:ncbi:9606">patients</span>
Identification of host genetic factors, including inherited, highly penetrant mutations in cancer susceptibility for hereditary breast cancer (BRCA1, BRCA2), familial polyposis coli (APC), and those predisposing to hereditary non-polyposis colon cancer, among others, in combination with knowledge of environmental factors, have the potential to reduce cancer morbidity and mortality by early detection and prevention [5,6,9,10,89-91]. In contrast to inherited mutations in relatively uncommon susceptibility genes, less is known concerning temporal progression of somatic genetic abnormalities in more prevalent sporadic premalignant conditions. Genetic progression models have been proposed for many types of cancers based largely on cross-sectional data [11,13,14,92-104]. TP53, CDKN2A, and DNA content (tetraploidy and aneuploidy) abnormalities are among the most common abnormalities in cancers and premalignant conditions affecting multiple organs, including head and neck, lung, breast, bladder, and pancreas, among others [1,71-73]. Few data exist as to their ability to predict future cancer or how these lesions can be modulated by chemoprevention efforts. Advances have been made in cancer risk prediction for patients with oral premalignant lesions in multiple retrospective, longitudinal studies [13-16]. Lee et al. combined multiple biomarkers and patient characteristics in Cox regression analysis and found that chromosome polyploidy, together with high p53 expression, LOH, and histology was the best predictor of cancer risk in a 10-y study of 70 patients with 22 cancer outcomes [13]. Thus, genetic progression models may be a rich source of hypotheses for retrospective longitudinal and prospective biomarker validation studies.
###end p 65
###begin p 66
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b004">4</xref>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b026">26</xref>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b027">27</xref>
###xml 232 235 232 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b105">105</xref>
###xml 236 239 236 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b111">111</xref>
###xml 328 332 328 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b079">79</xref>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b025">25</xref>
###xml 1763 1771 <span type="species:ncbi:9606">patients</span>
In experimental model systems and observational studies, aspirin and other NSAIDs have been reported to inhibit cyclo-oxygenase 2, increase apoptosis, decrease inflammation, decrease proliferation, and inhibit angiogenesis [4,26,27,105-111]. It has recently been shown that the absolute size of aneuploid clones and clones with TP53 lesions is a risk factor for progression to EA [79]. NSAIDs may act by reducing clone size through increasing apoptosis and decreasing angiogenesis and proliferation. By increasing apoptosis, NSAIDs may decrease the generation of viable clones, thus decreasing diversity and limiting the pool of genetic variants on which natural selection may act. In addition, NSAIDs function to reduce inflammation, which may in turn reduce the mutation rate in evolving clones and decrease the number of cellular variants. The cohort analyzed in the present report is a subset of that described in Vaughan et al. [25]. Of the molecular cohort described in the present study, 65% were current NSAID users-including use in follow-up-and this proportion is comparable with the 63% regular NSAID users (including use in follow-up) in the total cohort. About half of the users took aspirin for reasons concerning cardiovascular health, and the vast majority of the other users primarily took ibuprofen for pain relief. In a previous paper, we reported a strong protective association for EA with current NSAID use (at baseline or during follow-up), a rather rapid diminution of the association among former users, and no evidence of a stronger association with increasing frequency and/or duration of use. Furthermore, we did not find significant differences in risk of EA or aneuploidy according to type of NSAID. Thus for the present report, our patients were classified simply as NSAID user or nonuser (former or never) based on use at least once per week for >/=6 mo any time during follow-up, regardless of daily frequency, duration, or type. By focusing on the salient results from the previous analyses of a larger dataset regarding NSAIDs, we avoided multiple comparisons and could focus on the relationship of NSAID use with the status of molecular abnormalities.
###end p 66
###begin p 67
###xml 89 101 <span type="species:ncbi:9606">participants</span>
###xml 198 206 <span type="species:ncbi:9606">patients</span>
###xml 444 456 <span type="species:ncbi:9606">participants</span>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
Our results show a protective association between NSAID use and progression to EA in all participants, and particularly among those with multiple somatic genetic abnormalities. The vast majority of patients in this cohort had gastroesophageal reflux disease and were undergoing therapy, predominately using proton pump-inhibitors, to reduce reflux symptoms. It is unclear as to how the frequency or severity of symptoms may affect NSAID use by participants. However, to our knowledge, symptoms from reflux are not associated with intermediate endpoints or cancer in BE, so it is unlikely that symptoms could explain the association of NSAID use with reduced risk of EA. None of the patients had endoscopically visible concomitant conditions of the stomach, such as ulcers, at the baseline endoscopy that could have conceivably altered NSAID use. Given the experimental evidence provided in model systems and in previous studies, we propose that NSAIDs act within the BE tissue to modulate progression to EA. Our study is early translational research, as defined by the National Cancer Institute Translational Research Working Group (). These results advance our understanding of the molecular mechanisms of neoplastic progression as well as the mechanisms by which aspirin and other NSAIDs may prevent cancer. As such, these results are consistent with the National Institutes of Health goals of prevention, prediction, and personalized medicine. Several other types of research will be essential for these results to reach the clinic: multicenter randomized trials with a mechanistic focus to determine the effects of aspirin or other NSAIDs on progression to EA and intermediate endpoints (high-risk biomarkers), health services research to evaluate the effect of the interventions as well as the cost effectiveness of biomarkers that reduce frequencies of endoscopy and numbers of biopsies, and establishment of reimbursement mechanisms to support dissemination and adoption (National Cancer Institute's translational continuum; ).
###end p 67
###begin p 68
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b009">9</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b010">10</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b021">21</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b025">25</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b089">89</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b091">91</xref>
###xml 304 307 304 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b112">112</xref>
###xml 308 311 308 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b116">116</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b025">25</xref>
###xml 788 791 788 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040067-b117">117</xref>
###xml 502 510 <span type="species:ncbi:9606">patients</span>
###xml 648 656 <span type="species:ncbi:9606">patients</span>
###xml 723 731 <span type="species:ncbi:9606">patients</span>
###xml 1232 1240 <span type="species:ncbi:9606">patients</span>
###xml 1421 1429 <span type="species:ncbi:9606">patients</span>
Our study builds on a body of observational research, a recent meta-analysis, and supportive data in other cancers, most notably colon cancer where several clinical trials have reported a protective association of aspirin and other NSAIDs, although some findings have been inconsistent [9,10,21-25,89-91,112-116]. The present study extends these findings by evaluating the association of NSAID use with somatic genetic events that define progression in BE and demonstrates the benefits of NSAID use in patients at high risk of progressing to EA. Our results are consistent with previous results showing a protective effect on the part of NSAIDs in patients with HGD [25], and with computer models indicating that high-risk patients are the most likely to benefit from NSAID intervention [117]. The incidence of EA is sufficiently low in BE that designing statistically rigorous, adequately powered prevention studies with cancer as an endpoint is not feasible for most research cohorts. Thus, knowledge of the interaction of NSAIDs and somatic genetic abnormalities will help define entry criteria for randomized intervention trials with a cancer endpoint. The combination of a somatic genetic biomarker panel that identifies those patients with BE who are at high risk of progression to EA, combined with an inexpensive, widely available, and relatively safe means of preventing neoplastic progression in such high-risk patients, could have significant public health and economic benefits.
###end p 68
###begin title 69
Supporting Information
###end title 69
###begin title 70
Accession Numbers
###end title 70
###begin p 71
###xml 75 85 75 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 (p53)</italic>
###xml 121 124 121 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARF</sup>
###xml 94 124 94 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A (p16, p16-INK4a)/p14<sup>ARF</sup></italic>
###xml 137 141 137 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIC1</italic>
The GenBank () accession numbers for the genes discussed in this paper are TP53 (p53) (7157), CDKN2A (p16, p16-INK4a)/p14ARF (1029), and HIC1 (3090).
###end p 71
###begin p 72
###xml 28 40 <span type="species:ncbi:9606">participants</span>
###xml 175 182 <span type="species:ncbi:9606">patient</span>
We thank foremost the study participants who have made this study possible. We thank Janine Kikuchi, Terri Watson, and David Cowan for database support; Christine Karlsen for patient care coordination; Valerie Cerera for research biopsy coordination and flow cytometry; Laura Prevo, Jessica Arnaudo, and Heather Kissel for molecular assays; and Tricia Christopherson for interview management.
###end p 72
###begin title 73
Abbreviations
###end title 73
###begin p 74
Barrett's esophagus
###end p 74
###begin p 75
confidence interval
###end p 75
###begin p 76
esophageal adenocarcinoma
###end p 76
###begin p 77
high-grade dysplasia
###end p 77
###begin p 78
loss of heterozygosity
###end p 78
###begin p 79
nonsteroidal anti-inflammatory drug
###end p 79
###begin p 80
relative risk
###end p 80
###begin title 81
References
###end title 81
###begin article-title 82
Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development
###end article-title 82
###begin article-title 83
Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers
###end article-title 83
###begin article-title 84
Phases of biomarker development for early detection of cancer
###end article-title 84
###begin article-title 85
Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention
###end article-title 85
###begin article-title 86
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2
###end article-title 86
###begin article-title 87
Chemoprevention in hereditary colorectal cancer syndromes
###end article-title 87
###begin article-title 88
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Genetic testing for high-risk colon cancer patients
###end article-title 88
###begin article-title 89
Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer
###end article-title 89
###begin article-title 90
Primary chemoprevention of familial adenomatous polyposis with sulindac
###end article-title 90
###begin article-title 91
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
###end article-title 91
###begin article-title 92
Genetic progression model for head and neck cancer: Implications for field cancerization
###end article-title 92
###begin article-title 93
Genetic progression and clonal relationship of recurrent premalignant head and neck lesions
###end article-title 93
###begin article-title 94
Predicting cancer development in oral leukoplakia: Ten years of translational research
###end article-title 94
###begin article-title 95
Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia
###end article-title 95
###begin article-title 96
Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment
###end article-title 96
###begin article-title 97
Detection of chromosome instability of tissue fields at risk: In situ hybridization
###end article-title 97
###begin article-title 98
Demographic variations in the rising incidence of esophageal adenocarcinoma in white males
###end article-title 98
###begin article-title 99
Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995
###end article-title 99
###begin article-title 100
Epidemiologic trends in esophageal and gastric cancer in the United States
###end article-title 100
###begin article-title 101
Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus
###end article-title 101
###begin article-title 102
Aspirin use and cancers of the upper aerodigestive tract
###end article-title 102
###begin article-title 103
Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis
###end article-title 103
###begin article-title 104
Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: A meta-analysis
###end article-title 104
###begin article-title 105
NSAID use, BMI, and anthropometry in relation to genetic and cell cycle abnormalities in Barrett's Esophagus
###end article-title 105
###begin article-title 106
Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: A prospective study
###end article-title 106
###begin article-title 107
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus
###end article-title 107
###begin article-title 108
###xml 93 97 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats
###end article-title 108
###begin article-title 109
Evolution of neoplastic cell lineages in Barrett oesophagus
###end article-title 109
###begin article-title 110
Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma
###end article-title 110
###begin article-title 111
Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma
###end article-title 111
###begin article-title 112
p16 INK4a lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium
###end article-title 112
###begin article-title 113
p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus
###end article-title 113
###begin article-title 114
Losses of heterozygosity on chromosomes 9p and 17p are frequent events in Barrett's metaplasia not associated with dysplasia or adenocarcinoma
###end article-title 114
###begin article-title 115
17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus
###end article-title 115
###begin article-title 116
Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue
###end article-title 116
###begin article-title 117
Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus
###end article-title 117
###begin article-title 118
###xml 108 116 <span type="species:ncbi:9606">patients</span>
Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus
###end article-title 118
###begin article-title 119
Reduction to homozygostiy involving p53 in esophageal cancers demonstrated by the polymerase chain reaction
###end article-title 119
###begin article-title 120
Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus
###end article-title 120
###begin article-title 121
Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. The Rotterdam Oesophageal Tumour Study Group
###end article-title 121
###begin article-title 122
Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus
###end article-title 122
###begin article-title 123
###xml 148 156 <span type="species:ncbi:9606">patients</span>
DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: Thirteen-year follow-up study on a cohort of patients
###end article-title 123
###begin article-title 124
###xml 126 133 <span type="species:ncbi:9606">patient</span>
Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets
###end article-title 124
###begin article-title 125
###xml 108 115 <span type="species:ncbi:9606">patient</span>
Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression
###end article-title 125
###begin article-title 126
Predictors of progression in Barrett's esophagus III: Baseline flow cytometric variables
###end article-title 126
###begin article-title 127
Biomarkers in Barrett's Esophagus
###end article-title 127
###begin article-title 128
Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia
###end article-title 128
###begin article-title 129
Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota
###end article-title 129
###begin article-title 130
###xml 37 45 <span type="species:ncbi:9606">patients</span>
Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: A prospective study
###end article-title 130
###begin article-title 131
Barrett's esophagus: Age, prevalence, and extent of columnar epithelium
###end article-title 131
###begin article-title 132
The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland Clinic
###end article-title 132
###begin article-title 133
Barrett's esophagus, dysplasia, and adenocarcinoma
###end article-title 133
###begin article-title 134
Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR
###end article-title 134
###begin article-title 135
###xml 3 8 3 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">INK4a</sup>
p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas
###end article-title 135
###begin article-title 136
###xml 81 86 <span type="species:ncbi:9606">human</span>
Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest
###end article-title 136
###begin article-title 137
p53-mutant clones and field effects in Barrett's esophagus
###end article-title 137
###begin article-title 138
Controlling the false discovery rate: A practical and powerful approach to multiple testing
###end article-title 138
###begin article-title 139
Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer
###end article-title 139
###begin article-title 140
Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia
###end article-title 140
###begin article-title 141
Meta-analysis: Obesity and the risk for gastroesophageal reflux disease and its complications
###end article-title 141
###begin article-title 142
Association between body mass and adenocarcinoma of the esophagus and gastric cardia
###end article-title 142
###begin article-title 143
###xml 0 7 <span type="species:ncbi:4097">Tobacco</span>
Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia
###end article-title 143
###begin article-title 144
###xml 11 18 <span type="species:ncbi:4097">tobacco</span>
###xml 115 118 <span type="species:ncbi:9606">men</span>
###xml 123 128 <span type="species:ncbi:9606">women</span>
Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study
###end article-title 144
###begin article-title 145
###xml 12 19 <span type="species:ncbi:4097">tobacco</span>
The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia
###end article-title 145
###begin article-title 146
A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States)
###end article-title 146
###begin article-title 147
Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma
###end article-title 147
###begin article-title 148
Population attributable risks of esophageal and gastric cancers
###end article-title 148
###begin article-title 149
Prospective study of cyclin D1 overexpression in Barrett's esophagus: Association with increased risk of adenocarcinoma
###end article-title 149
###begin article-title 150
Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk
###end article-title 150
###begin article-title 151
TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort
###end article-title 151
###begin article-title 152
Principles of tumor suppression
###end article-title 152
###begin article-title 153
INK4a/ARF: A multifunctional tumor suppressor locus
###end article-title 153
###begin article-title 154
The IARC TP53 database: New online mutation analysis and recommendations to users
###end article-title 154
###begin article-title 155
###xml 40 45 <span type="species:ncbi:9606">human</span>
Common patterns of genetic evolution in human solid tumors
###end article-title 155
###begin article-title 156
p53: Puzzle and paradigm
###end article-title 156
###begin article-title 157
Natural selection in neoplastic progression of Barrett's esophagus
###end article-title 157
###begin article-title 158
Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus
###end article-title 158
###begin article-title 159
The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma
###end article-title 159
###begin article-title 160
Biomarkers of esophageal adenocarcinoma and Barrett's esophagus
###end article-title 160
###begin article-title 161
Focus on Barrett's esophagus and esophageal adenocarcinoma
###end article-title 161
###begin article-title 162
Biomarkers in Barrett's esophagus (review)
###end article-title 162
###begin article-title 163
p53 and neoplastic progression in Barrett's esophagus
###end article-title 163
###begin article-title 164
p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: Immunohistochemical marker predictive of progression
###end article-title 164
###begin article-title 165
Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens
###end article-title 165
###begin article-title 166
p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3
###end article-title 166
###begin article-title 167
Specific contribution of p19(ARF) to nitric oxide-dependent apoptosis
###end article-title 167
###begin article-title 168
Genetic clonal diversity predicts progression to esophageal adenocarcinoma
###end article-title 168
###begin article-title 169
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
###end article-title 169
###begin article-title 170
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis
###end article-title 170
###begin article-title 171
###xml 173 181 <span type="species:ncbi:9606">patients</span>
A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients
###end article-title 171
###begin article-title 172
Independent origin of multiple foci of prostatic intraepithelial neoplasia: Comparison with matched foci of prostate carcinoma
###end article-title 172
###begin article-title 173
Genetic pattern of prostate cancer progression
###end article-title 173
###begin article-title 174
p16 and p53 gene alterations and accumulations in the malignant evolution of intraductal papillary-mucinous tumors of the pancreas
###end article-title 174
###begin article-title 175
Genetic mechanisms of hepatocarcinogenesis
###end article-title 175
###begin article-title 176
Distribution of genetic variants in preneoplastic areas of colorectal tumours
###end article-title 176
###begin article-title 177
Genetic pathways in the evolution of breast ductal carcinoma in situ
###end article-title 177
###begin article-title 178
Loss of heterozygosity in benign breast epithelium in relation to breast cancer risk
###end article-title 178
###begin article-title 179
Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer
###end article-title 179
###begin article-title 180
Pathways of urothelial cancer progression suggested by Bayesian network analysis of allelotyping data
###end article-title 180
###begin article-title 181
###xml 20 25 <span type="species:ncbi:9606">human</span>
Genetic modeling of human urinary bladder carcinogenesis
###end article-title 181
###begin article-title 182
###xml 35 40 <span type="species:ncbi:9606">human</span>
Molecular genetic changes found in human lung cancer and its precursor lesions
###end article-title 182
###begin article-title 183
Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression
###end article-title 183
###begin article-title 184
A genetic model for colorectal tumorigenesis
###end article-title 184
###begin article-title 185
Aspirin induction of apoptosis in esophageal cancer: A potential for chemoprevention
###end article-title 185
###begin article-title 186
###xml 84 89 <span type="species:ncbi:9606">human</span>
Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells
###end article-title 186
###begin article-title 187
The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: An in vitro study
###end article-title 187
###begin article-title 188
Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues
###end article-title 188
###begin article-title 189
NSAID inhibition of GI cancer growth: Clinical implications and molecular mechanisms of action
###end article-title 189
###begin article-title 190
Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus
###end article-title 190
###begin article-title 191
Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in BE
###end article-title 191
###begin article-title 192
A randomized trial of aspirin to prevent colorectal adenomas
###end article-title 192
###begin article-title 193
###xml 64 72 <span type="species:ncbi:9606">patients</span>
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer
###end article-title 193
###begin article-title 194
###xml 58 63 <span type="species:ncbi:9606">Women</span>
Low-dose aspirin in the primary prevention of cancer: The Women's Health Study: A randomized controlled trial
###end article-title 194
###begin article-title 195
Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence
###end article-title 195
###begin article-title 196
Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians' Health Study
###end article-title 196
###begin article-title 197
Medical decision analysis of chemoprevention against esophageal adenocarcinoma
###end article-title 197
###begin title 198
Figures and Tables
###end title 198
###begin title 199
###xml 35 47 <span type="species:ncbi:9606">Participants</span>
Modulation of EA Risk by NSAIDs in Participants with Different Baseline Abnormalities
###end title 199
###begin p 200
###xml 103 104 103 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 184 185 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 214 215 214 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 26 34 <span type="species:ncbi:9606">patients</span>
###xml 389 397 <span type="species:ncbi:9606">patients</span>
Two hundred and forty-one patients are classified according to whether they have (A) baseline 17p LOH (n = 46), (B) baseline DNA content abnormalities (aneuploidy and/or tetraploidy) (n = 41), (C) baseline 9p LOH (n = 144), or (D) more than one baseline abnormality (top two curves) or one or less abnormality (lower two curves). Shown are Kaplan-Meier curves of cancer incidence rates in patients who are NSAID nonusers (former or never users, red curves) or NSAID users (current or user during follow-up, black curves).
###end p 200
###begin title 201
Cumulative EA Incidence with Combinations of Abnormalities (17p LOH, DNA Content Abnormality, 9p LOH) in NSAID Nonusers and NSAID Users
###end title 201
###begin p 202
###xml 507 508 507 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 37 49 <span type="species:ncbi:9606">participants</span>
###xml 298 310 <span type="species:ncbi:9606">participants</span>
Cancer incidence rates are shown for participants with no selected abnormalities (17p LOH, DNA content abnormalities [aneuploidy and/or tetraploidy], or 9p LOH) at baseline (red), any one abnormality (green), any combination of two abnormalities (blue), or all three abnormalities (black). (A) All participants. When comparing NSAID nonusers (B) and NSAID users (C) there is a strong significant trend toward EA risk reduction in the NSAID users group for all abnormality combinations (Mantel-Haenszel test p = 0.01).
###end p 202
###begin p 203
Cohort Characteristics
###end p 203
###begin p 204
Univariate Analysis of RR for EA during Follow-up
###end p 204
###begin p 205
Stepwise Selection for Molecular Markers and RR for EA of Final Selected Markers
###end p 205
###begin p 206
Cumulative EA Incidence and RR of Different Baseline Abnormality Combinations
###end p 206
###begin p 207
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 207
###begin p 208
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
###xml 301 309 <span type="species:ncbi:9606">patients</span>
Author contributions. PCG, PLB, CAS, TLV, and BJR contributed to conception and design of the study. PCG, PLB, CAS, KA, TLV, and BJR collected data or did experiments for the study. PCG, XL, CCM, CAS, RDO, PSR, TLV, and BJR contributed to analysis and interpretation of the data. PLB and BJR enrolled patients. PCG, XL, PLB, CCM, CAS, RDO, KA, PSR, TLV, and BJR contributed to drafting the article or revising it critically. All authors approved the final accepted version of the manuscript.
###end p 208
###begin p 209
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: This study was funded by the US National Institutes of Health (P01 CA91955, R01 CA61202, and R01 CA78828) with interim support from the Fred Hutchinson Cancer Research Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 209

